Progyny Q1 2026 revenue hits record $328.5 million; net income rises to $24.2 million
Progyny reported first quarter 2026 revenue of $328.5 million, up 1.4%, and net income of $24.2 million, or $0.29 per diluted share, compared with $15.1 million, or $0.17, a year earlier. Adjusted EBITDA fell 2.1% to $56.6 million as the company made planned platform investments, and the company issued full-year 2026 guidance with revenue of $1.365 billion to $1.405 billion.
Key points
- Revenue was $328.5 million, up 1.4% from $324.0 million; excluding $31.3 million from a large client in the prior-year period, revenue rose 12.2%.
- Net income was $24.2 million, or $0.29 per diluted share, versus $15.1 million, or $0.17, in Q1 2025; Adjusted EBITDA was $56.6 million, down 2.1%.
- The November 2025 share repurchase program ($200 million authorization) is complete, with 8.8 million shares bought; the board expects a decision on a new program around the end of May.
- Full-year 2026 guidance: revenue of $1.365 billion to $1.405 billion, net income of $103.7 million to $112.3 million, and Adjusted EBITDA of $232.0 million to $244.0 million.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.